A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump

Alza Corporation

Status and phase

Completed

Phase 3

Conditions

Pain, Postoperative

Analgesia

Treatments

Drug: E-TRANS Fentanyl hydrochloride; Morphine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00264485

CR004720

Details and patient eligibility

About

The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled analgesia (PCA) management systems: the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) and the morphine intravenous pump. Fentanyl HCl and morphine are narcotic pain relievers. The E-TRANS fentanyl system is a small unit worn on the patient's upper outer arm or chest that uses low-intensity electrical current to deliver fentanyl through the skin and into the patient's bloodstream. The patients studied will be those who have just received a total hip replacement.

Full description

The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled analgesia (PCA). PCA is a form of pain management that allows the patient to control the amount of pain medication he or she receives. The PCA E-TRANS fentanyl system is a credit card-sized unit that is worn on the patient's upper outer arm or chest. It uses low-intensity electrical current to move fentanyl through the skin and into the patient's bloodstream. It does not require the insertion of an intravenous (IV) needle, or injection for pain management. PCA IV morphine is delivered into a vein by an IV infusion pump that is specially designed to be controlled by the patient. The PCA E-TRANS fentanyl system delivers a 40 microgram dose of fentanyl and the PCA IV morphine delivers a 1 milligram intravenous dose of morphine. The patients in this study are those scheduled for a total hip replacement in one (not both) hips. Before surgery, patients will be taught how to use both PCA devices and randomly assigned to receive either PCA IV morphine or E-TRANS fentanyl. After undergoing the hip replacement, patients will have the PCA device applied to the skin (E-TRANS fentanyl) or an IV inserted into a vein (PCA IV morphine), according to the random assignment. The patient will then be allowed to control delivery of the assigned medication for 72 hours. During the first 24 hours, the patient will be asked about the amount of pain he or she is having. The primary measure of effectiveness is successful pain relief (defined by a rating of "Excellent", or "Good") on the 24-hour patient global assessment of the method of pain control. At 24, 48, and 72 hours, the patient will be asked a set of specific questions to measure the effectiveness of the PCA. In addition, the patient's doctor, nurses, and physical therapists will answer questions about the PCA system. Safety will be assessed by monitoring the patient's vital signs and recording any adverse events, including problems at the location on the patient's body where the PCA device has been applied or inserted. The objective is to establish that the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) is as effective as intravenous (IV) PCA morphine in controlling pain after a total hip replacement.

E-TRANS fentanyl 40 mcg transdermally per patient-activated dose over 10 minutes, up to 6 doses per hour or a maximum of 80 doses in 24 hours; Patient controlled intravenous morphine 1 mg dose, up to 10 doses per hour or a maximum of 240 doses in 24 hours. Study duration is 72 hours.

Enrollment

799 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a pre-operative American Society of Anesthesiology Physical Status I, II, or III (Class I are healthy persons less than 80 years of age, Class II are patients over age 80 years of age with mild systemic disease, and Class III are patients with severe and non-incapacitating disease)
Admitted to the Post-Anesthesia Care Unit after general or spinal anesthesia (using bupivacaine)
Surgical time of up to 4 hours for total hip replacement surgery with a single surgical incision
Awake and breathing spontaneously, with a respiratory rate of 8 to 24 breaths per minute and oxygen saturation of 90% or higher (with or without supplemental oxygen)
Expected to remain hospitalized for at least 24 hours postoperatively

Exclusion criteria

Patients whose post-operative pain would normally be managed with oral or non-narcotic pain medication
Who received intraoperative spinal anesthesia other than bupivacaine (without epinephrine), intraoperative epidural anesthesia, or who are expected to have postoperative analgesia supplied by a continuous regional technique
Have a history of allergy, hypersensitivity, or tolerance to fentanyl or morphine, or a history of allergy or hypersensitivity to cetylpyridinium chloride or skin adhesives, or have the presence of active skin disease that would interfere with application of the E-TRANS fentanyl system
Who received systemic or intra-articular steroids within 1 month before surgery or during surgery
Expected to require intensive care postoperatively or who will probably need additional surgical procedures within 72 hours